Advertisement

Topics

Bioverativ Inc. and Sobi Company Profile

10:37 EST 23rd January 2019 | BioPortfolio

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.


News Articles [91 Associated News Articles listed on BioPortfolio]

Jefferies Healthcare Conference 2018: SOBI bets on the haemophilia market

In 2006, Swedish Orphan Biovitrum (SOBI) partnered with Bioverativ to develop a new generation of haemophilia treatments. Their leading treatments,...Read More... The post Jefferies Healthcare Confere...

At ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and ...

STOCKHOLM, Dec. 2, 2018 /PRNewswire/ -- Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, Read more...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orp...

Bioverativ reports on preliminary data for factor VIII candidate

Preliminary results from a Phase I/IIa study showed that one dose of Bioverativ's BIVV001, or rFVIIIFc-VWF-XTEN, resulted in  -More- 

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ continues sell-off, SOBI spies US expansion

AstraZeneca Sells Synagis Rights to Sobi

Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion ...

Sobi tar klivet in bland större läkemedelsbolag

Sobi meddelade i mitten av november att man köper rättigheterna till ett läkemedel från Astra- Zeneca med den största marknadsandelen i USA.

Sobi gains exclusive US rights to AZ's Synagis; deal value tops $2.3bn

AstraZeneca PLC sold Swedish Orphan Biovitrum AB (Sobi) exclusive rights to commercialize the respiratory syncytial virus therapy Synagis (palivizumab) in the US. Sobi will also participate in AZ’s ...

Drugs and Medications [3 Associated Drugs and Medications listed on BioPortfolio]

Orfadin [SWEDISH ORPHAN BIOVITRUM AB (PUBL)]

These highlights do not include all the information needed to use ORFADIN safely and effectively. See full prescribing information for ORFADIN. ORFADIN (nitisinone) capsules, for oral useORFADIN (niti...

Kepivance [Swedish Orphan Biovitrum AB (publ)]

These highlights do not include all the information needed to use Kepivance safely and effectively. See full prescribing information for KEPIVANCE. KEPIVANCE (palifermin) for injection, for intravenou...

Orfadin [Swedish Orphan Biovitrum AB (publ)]

These highlights do not include all the information needed to use ORFADIN safely and effectively. See full prescribing information for ORFADIN. ORFADIN (nitisinone) capsules, for oral useORFADIN (niti...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [10 Associated Companies listed on BioPortfolio]

Bioverativ Inc. and Sobi

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class re...

Bioverativ Inc. & Sobi

Bioverativ (NASDAQ: BIVV) is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class re...

Swedish Orphan Biovitrum AB

Sobi is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. Sobi have a diversi...

Bioverativ Inc.,

Bioverativ, a Sanofi company, is dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development, and commer...

Bioverativ Inc.

Bioverativ (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class resear...

More Information about "Bioverativ Inc. and Sobi" on BioPortfolio

We have published hundreds of Bioverativ Inc. and Sobi news stories on BioPortfolio along with dozens of Bioverativ Inc. and Sobi Clinical Trials and PubMed Articles about Bioverativ Inc. and Sobi for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bioverativ Inc. and Sobi Companies in our database. You can also find out about relevant Bioverativ Inc. and Sobi Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record